Compare Danaos Corporation (DAC) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaos Corporation vs ResMed Inc. — how do they compare? Danaos Corporation trades at $128.75 (market cap $2.36B), while ResMed Inc. trades at $197.53 (market cap $28.00B). The key difference: ResMed Inc. is far larger — about 11.9× Danaos Corporation's market cap, and Danaos Corporation pays the higher dividend (2.78%). Which is the better fit depends on your goals.
| DAC | RMD | |
|---|---|---|
Market Cap | $2.36B | $28.00B |
Sector | Technology | Health |
52-Week High | $134.63 | $293.73 |
52-Week Low | $84.05 | $182.82 |
Enterprise Value | $2.36B | $27.18B |
Dividend Yield | 2.78% | 1.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaos Corporation (DAC) trades at $129.35, up 0.75% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 4.57, P/B of 0.6, and net income margin of 49.85% (2026 trend). Recent Q1 2026 earnings beat expectations, and the company maintains a consistent dividend policy. Analyst sentiment is mixed with a 40% buy rating. The stock is near resistance at $130, with RSI_6 indicating potential overbought conditions.
The outlook for DAC remains positive due to attractive valuation, high profitability, and a robust containership backlog. Key risks include exposure to shipping rate volatility and capital allocation decisions. Upside potential is supported by earnings momentum and dividend yield, but investors should monitor industry cyclicality and execution on fleet expansion.
ResMed (RMD) trades at $198.50, down 2.63% on the day, with technical indicators showing a bearish trend near support at $197. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $2.86 versus $2.80 expected, and robust profitability with a 27.44% net margin. Recent strategic moves include the sale of its MatrixCare business for $490 million to sharpen focus on core sleep and respiratory care markets.
The outlook remains positive given analyst consensus targets near $249.57, representing significant upside, though near-term technical weakness and competitive pressures in digital health pose risks. Revenue growth is projected to reach $5.5 billion in 2026, supporting a solid investment case for long-term holders despite current bearish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaos Corporation
Danaos is a leading international owner of containerships, providing seaborne transportation services globally. It charters its fleet of vessels to major shipping lines across Asia, Europe, and the Americas.
Read more on DAC →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
